EDWARDS LIFESCIENCES CORP (NYSE: EW)

EDWARDS LIFESCIENCES CORP

NYSE: EW (Edwards Lifesciences Corporatio)

Last update: 11 hours ago

84.49

0.31 (0.37%)

Add to watchlist

Previous Close	84.17
Open	85.00
Volume	41,554
Avg. Volume (3M)	3,947,685
Market Cap	49,601,146,880

Price / Earnings (TTM)	37.05
Price / Earnings (Forward)	30.03
Price / Sales	8.53
Price / Book	4.85

52 Weeks Range	65.94 (-21%) — 87.89 (4%)
Earnings Date	30 Oct 2025

Market Trend

		Short Term	Medium Term
Industry	Medical Devices (US)	Mixed	Mixed
	Medical Devices (Global)	Mixed	Mixed
Stock	Edwards Lifesciences Corporatio	Bullish	Bullish

AIStockmoo Score

0.3

Analyst Consensus	5.0
Insider Activity	NA
Price Volatility	-3.5
Technical Moving Averages	0.0
Technical Oscillators	-0.5
Average	0.25

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
EW	50 B	-	37.05	4.85
SNN	14 B	2.04%	29.10	2.54
BSX	142 B	-	50.79	6.04
SYK	133 B	0.24%	45.89	6.11
PHG	26 B	-	142.68	2.10
ABT	220 B	0.47%	15.91	4.24

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Sector	Healthcare
Industry	Medical Devices
Investment Style	Mid Growth
% Held by Insiders	0.91%
% Held by Institutions	89.29%

Ownership

Name	Date	Shares Held
Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt	30 Sep 2025	9,240,197

52 Weeks Range	65.94 (-21%) — 87.89 (4%)
Price Target Range	87.00 (2%) — 104.00 (23%)
High	104.00 (Goldman Sachs, 23.10%)	Buy
Median	99.00 (17.18%)
Low	87.00 (Canaccord Genuity, 2.98%)	Hold
	87.00 (Baird, 2.98%)	Hold
Average	96.88 (14.67%)
Total	12 Buy, 4 Hold
Avg. Price @ Call	84.57

Firm	Date	Target Price	Call	Price @ Call
JP Morgan	18 Dec 2025	100.00 (18.36%)	Buy	84.80
JP Morgan	31 Oct 2025	90.00 (6.53%)	Hold	82.45
Canaccord Genuity	17 Dec 2025	87.00 (2.98%)	Hold	84.84
Canaccord Genuity	05 Dec 2025	89.00 (5.34%)	Hold	86.19
Baird	16 Dec 2025	87.00 (2.98%)	Hold	85.32
Baird	05 Dec 2025	88.00 (4.16%)	Hold	86.19
Citigroup	11 Dec 2025	101.00 (19.55%)	Buy	84.24
Citigroup	31 Oct 2025	96.00 (13.63%)	Buy	82.45
Barclays	08 Dec 2025	103.00 (21.92%)	Buy	84.32
Barclays	31 Oct 2025	99.00 (17.18%)	Buy	82.45
BTIG	05 Dec 2025	103.00 (21.92%)	Buy	86.19
BTIG	25 Nov 2025	100.00 (18.36%)	Buy	86.82
RBC Capital	05 Dec 2025	100.00 (18.36%)	Buy	86.19
RBC Capital	31 Oct 2025	95.00 (12.45%)	Buy	82.45
Stifel	05 Dec 2025	100.00 (18.36%)	Buy	86.19
Stifel	31 Oct 2025	95.00 (12.45%)	Buy	82.45
Truist Securities	05 Dec 2025	92.00 (8.90%)	Hold	86.19
Truist Securities	03 Nov 2025	90.00 (6.53%)	Hold	83.07
UBS	05 Dec 2025	92.00 (8.90%)	Hold	86.19
Wells Fargo	05 Dec 2025	96.00 (13.63%)	Buy	86.19
Evercore ISI Group	31 Oct 2025	92.00 (8.90%)	Buy	82.45
Evercore ISI Group	07 Oct 2025	88.00 (4.16%)	Buy	76.72
Goldman Sachs	31 Oct 2025	104.00 (23.10%)	Buy	82.45
Mizuho	31 Oct 2025	100.00 (18.36%)	Buy	82.45
Piper Sandler	31 Oct 2025	95.00 (12.45%)	Buy	82.45
Jefferies	29 Oct 2025	98.00 (16.00%)	Buy	82.69
Show more

No data within this time range.

Date	Type	Details
23 Dec 2025	Announcement	FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy
18 Dec 2025	Announcement	Edwards Lifesciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
04 Dec 2025	Announcement	Edwards Lifesciences Reaffirms Strategy for Sustainable, Differentiated Growth at Annual Investor Conference
09 Nov 2025	Announcement	Edwards Champions American Heart Association Initiative to Reduce Deaths, Improve Care for Patients With Heart Valve Disease
09 Nov 2025	Announcement	Driving Timely Diagnosis And Treatment For Heart Valve Disease To Save Lives
30 Oct 2025	Announcement	Edwards Lifesciences Announces CFO Transition Plan
30 Oct 2025	Announcement	Edwards Lifesciences Reports Third Quarter Results
27 Oct 2025	Announcement	Successful Patient Outcomes Demonstrated With Edwards’ SAPIEN M3 and EVOQUE Systems, New Data Presented at TCT 2025
27 Oct 2025	Announcement	Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025
23 Oct 2025	Announcement	Edwards Lifesciences to Host Earnings Conference Call on October 30, 2025

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2026	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Profit Margin	75.71%
Operating Margin (TTM)	29.01%
Diluted EPS (TTM)	2.42
Quarterly Revenue Growth (YOY)	6.20%
Quarterly Earnings Growth (YOY)	1.70%

Total Debt/Equity (MRQ)	6.86%
Current Ratio (MRQ)	4.45
Operating Cash Flow (TTM)	876.20 M
Levered Free Cash Flow (TTM)	1.45 B

Return on Assets (TTM)	8.42%
Return on Equity (TTM)	16.51%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)